Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis by van den Berg, Maarten P et al.
  
 University of Groningen
Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile
amyloidosis
van den Berg, Maarten P; Mulder, Bart A; Klaassen, Sebastiaan H C; Maass, Alexander H;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van den Berg, M. P., Mulder, B. A., Klaassen, S. H. C., Maass, A. H., van Veldhuisen, D. J., van der Meer,
P., ... Rienstra, M. (2019). Heart failure with preserved ejection fraction, atrial fibrillation, and the role of
senile amyloidosis. European Heart Journal, 40(16), 1287-1293. https://doi.org/10.1093/eurheartj/ehz057
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




























Heart failure with preserved ejection fraction,
atrial fibrillation, and the role of senile
amyloidosis
Maarten P. van den Berg1*, Bart A. Mulder1, Sebastiaan H.C. Klaassen1,
Alexander H. Maass1, Dirk J. van Veldhuisen1, Peter van der Meer1,
Hans L.A. Nienhuis2, Bouke P.C. Hazenberg3, and Michiel Rienstra1
1Department of Cardiology, Thorax Centre, University of Groningen, University Medical Centre Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands;
2Department of Internal Medicine, University of Groningen, University Medical Centre Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; and 3Department of
Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
Received 17 October 2018; revised 21 December 2018; editorial decision 10 January 2019; accepted 22 January 2019; online publish-ahead-of-print 8 February 2019
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are very common conditions, particularly in the elderly.
However, the mechanisms underlying the two disorders, including their intricate interaction have not been fully resolved. Here, our aim is
to review the evidence on the role of the two types of senile amyloidosis in this connection. Two types of senile amyloidosis can be iden-
tified: wild-type transthyretin (TTR)-derived amyloidosis (ATTRwt) and isolated atrial amyloidosis (IAA). ATTRwt is an underlying condi-
tion that is being increasingly recognized in patients with HFpEF and often accompanied by AF. IAA is an established cause of AF, adding
to the mechanism problem. New diagnostic and therapeutic possibilities have emerged that may facilitate clinical management of (senile)
amyloidosis, which in turn may have implications for the management of HFpEF and AF.
...................................................................................................................................................................................................
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Introduction
Heart failure is a rising epidemic in cardiovascular medicine, especially
heart failure with preserved ejection fraction (HFpEF) and the same
holds true for atrial fibrillation (AF).1 Importantly, both these disor-
ders often occur together, due to common associated conditions
and comorbidities. Moreover, there is an intricate interaction be-
tween the two disorders. On the one hand, HFpEF may cause AF by
increasing left atrial pressure, thereby atrial stretch/enlargement and
eventually fibrosis. On the other hand, AFmay precipitate overt heart
failure in the setting of diastolic dysfunction (‘HFpEF’), due to what-
ever cause. However, this is a simplification of the mechanisms
involved in the complex interplay between HFpEF and AF and new
insights are urgently needed.
Amyloidosis is a protein-misfolding disease characterized by extra-
cellular deposition of a soluble precursor protein that aggregates in
the form of insoluble fibrils, causing cell/tissue damage and ultimately
organ dysfunction. Over 30 different amyloidogenic proteins have
been identified, some of which affect the heart and cause ‘cardiac
amyloidosis’. In brief, the clinical hallmark of cardiac amyloidosis is
marked thickening and stiffening of the walls of the left and right ven-
tricles leading to diastolic dysfunction (‘restrictive physiology’). A
common type of amyloidosis is immunoglobulin light chain-derived
(AL amyloidosis), but we will not deal with this separately here. In re-
cent years, another type of amyloidosis has gained increasing atten-
tion: transthyretin (TTR)-derived amyloidosis (ATTR), which can be
divided into a hereditary type (ATTRm) and a wild-type (ATTRwt).
Whereas ATTRm is a rare disease, ATTRwt is relatively common
and is increasingly recognized as a cause of HFpEF in the elderly.
Moreover, ATTRwt is often accompanied by AF. Another type of
amyloidosis affecting the heart at advanced age is so-called isolated
atrial amyloidosis (IAA), which also sets the stage for AF. Our aim is
to review the evidence on the role of the two types of senile amyloid-
osis (ATTRwt and IAA) in HFpEF and AF.
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Transthyretin is a naturally occurring protein produced mainly by the
liver. It functions as a transport protein for thyroxine and retinol
binding protein. Transthyretin is a tetramer rich in ß strands and it
has an innate ability to aggregate into insoluble amyloid fibres. The
first step is dissociation of TTR into its monomers, followed by accu-
mulation of these monomers into oligomers, composed of 6–10
monomers. These oligomers may aggregate into amyloid fibres,
which in turn may be deposited in the extracellular matrix of various
tissues and organs, including the heart. Alterations in TTR due to
mutations in TTR, the gene encoding TTR, may increase the likelihood
of dissociation of TTR into its monomers—and hence their aggrega-
tion—and the development of amyloidosis (ATTRm), but we will not
deal separately with this disease here.
Ageing may also destabilize TTR, eventually also leading to amyl-
oidosis (ATTRwt), which was formerly known as senile systemic
amyloidosis (SSA). Following smaller studies in 1983, Cornwell et al.2
reported a study of 85 autopsies in patients >_80 years of age. They
showed the presence of TTR amyloid in as many as 25% of the (left)
ventricles. More recently, 25% was also reported in a Finnish group
of patients aged >_85 years (256 autopsies), supporting the notion
that ATTRwt is a very common finding in the very elderly.3 The
underlying mechanisms are still being debated, but may involve age-
related post-transcriptional biochemical alterations in TTR or its
chaperones.4,5
Amyloidosis transthyretin-derived
wild-type and heart failure with
preserved ejection fraction
Elaborating on the above data, Mohammed et al.6 investigated the fre-
quency of amyloid in ventricular specimens from patients with an
antemortem diagnosis of HFpEF. The presence of TTR (wild-type)
was associated with advanced age and male sex, and age- and sex-
adjusted prevalence was higher in HFpEF patients (n=109) than in
control subjects (n=131). Among the HFpEF patients, moderate or
severe interstitial amyloid deposition was present in 5% of them,
while mild interstitial and/or intramural coronary vascular deposition
was present in 12% of them.6 This landmark pathology study was
followed by a clinical study in HFpEF patients aged >60 years and
with left ventricular hypertrophy. All patients underwent 99mTc-DPD
scintigraphy to diagnose ATTR.7 A total of 16 patients (13%) showed
moderate-to-severe uptake on the scintigram, indicative of ATTR.7 In
addition, a longitudinal study in 121 patients with ATTRwt was re-
cently reported by Connors et al.,8 supporting the notion that
ATTRwt is associated with HFpEF. Over 20 years, they enrolled
patients with biopsy-proven ATTRwt in a prospective, observational
study. Age at enrolment was 76 years and 98% were male. Left ven-
tricular ejection fraction at baseline was on average preserved,
but the vast majority already had symptoms of heart failure. Median
survival was 47months and 78% of all these patients died from heart
failure or sudden death.
Theoretically, the mechanism underlying the occurrence of
HFpEF in the setting of ATTRwt would be advanced diastolic left
ventricular dysfunction secondary to the deposition of amyloid
fibrils in the extracellular matrix. Indeed, like in other types of
cardiac amyloidosis, ATTRwt is characterized by myocardial
thickening and reduced diastolic tissue velocities on echocardiog-
raphy, often amounting to a restrictive filling pattern,9 which was
confirmed by right-sided catheterization. Conversely, it cannot
be excluded that HFpEF per se promotes amyloid deposition due
to the associated pro-oxidative state leading to increased TTR
oxidation.
Amyloidosis transthyretin-derived
wild-type and atrial fibrillation
We identified five studies reporting the prevalence of AF in the set-
ting of cardiac amyloidosis due to ATTRwt (Table 1).10–14 Overall, al-
though the studies vary in terms of entry criteria, clinical
characteristics and numbers of subjects, cardiac amyloidosis due to
ATTRwt appears to be associated with a high prevalence of AF.
Moreover, the prevalence of AF in ATTRwt also appears to be higher
than the prevalence of AF in AL amyloidosis or ATTRm. Conversely,
the study by Longhi et al. also showed that AF may also precipitate
haemodynamic deterioration in the setting of amyloid cardiomyop-
athy. Indeed, despite comparable wall thickness, end-diastolic diam-
eter and atrial size in patients presenting with heart failure, cardiac
index was reduced in the subgroup of patients with AF, most likely
due to loss of atrial kick.11
The mechanism underlying the high prevalence of AF in ATTRwt
most likely involves atrial (ultra)structural remodelling, secondary to
diastolic left ventricular dysfunction and increased filling pressures,
even without overt HFpEF.15,16 Indeed, in the studies by Rapezzi
et al.10 and Longhi et al.11 atrial pressure and atrial size were inde-
pendent risk factors for the development of AF. Adding to these
studies, Barbhaiya et al.17 investigated the electrophysiological charac-
teristics of patients with cardiac amyloidosis and AF compared with
control patients with AF due to other aetiologies. The amyloid group
consisted of 18 patients with either AL amyloidosis (n=4) or
ATTRwt (n=14), and almost all patients had advanced diastolic dys-
function on echocardiography. Among other findings, the amyloid
.................................................................................................
Table 1 Frequency of atrial fibrillation in different







Rapezzi et al.10 233 12 5 27
Longhi et al.11 262 9 11 40
Pinney et al.12 138 16 NA 43
Kristen et al.13 216 16 18 30
Grogan et al.14 360 NA NA 62
The study by Longhi et al. was the only one to focus on atrial fibrillation. Another
limitation is that all five studies were retrospective.
AL, amyloidosis immunoglobulin light chain-derived; ATTRm, amyloidosis trans-
thyretin (TTR)-derived hereditary type; ATTRwt, amyloidosis transthyretin
(TTR)-derived wild-type; NA, not applicable.
































































































..patients showed prolonged conduction intervals (PR, AH, HV)
compared with the control group. In addition, in a subgroup
(n=7) endocardial atrial voltage mapping was performed, show-
ing extensive areas of low voltage and more so than in the control
patients (Figure 1).17 Finally, arrhythmia-free survival after cath-
eter ablation was significantly worse in the amyloid patients
compared with the control patients. These remarkable findings
would suggest that amyloid deposition in ATTRwt is perhaps not
confined to the ventricles, but this important point will be further
discussed below.
Isolated atrial amyloidosis and
atrial fibrillation
Most commonly, amyloidosis (including ATTRwt) is a systemic dis-
ease affecting various organs and tissues, which may include the heart,
but there is one particular type of amyloidosis which only affects the
heart. More specifically, this type of localized amyloidosis is confined
to the atria, hence its name isolated atrial amyloidosis. The incidence
of IAA increases with age, reaching >90% in the ninth decade,18–20
and it is therefore also considered to be a form of senile amyloidosis,
such as ATTRwt. The fibril protein that is deposited in IAA is atrial
natriuretic peptide (ANP), a naturally occurring peptide hormone
synthesized by atrial cardiomyocytes. A potent stimulus for ANP se-
cretion is AF, probably secondary to atrial stretch and perhaps also
due to fibrillatory activity per se. It is essentially still unknown why
ANPmay deposit as amyloid. In this connection, IAA does not appear
to be more common in patients with cardiovascular risk factors
(hypertension or diabetes mellitus), suggesting that IAA is a relatively
autonomic process. Nevertheless, IAA is a clinically relevant condi-
tion, in particular given its association with AF. In the first study that
systematically addressed this issue, Ro¨cken et al.21 investigated right
atrial appendages from 245 patients undergoing open heart surgery
(bypass surgery, valve surgery). Their mean age was 63 years, 174
were males, and persistent AF was present in 15% of the patients.
Amyloid was found in 16% of the patients and all deposits were
immunoreactive for ANP.21 The presence of amyloid was associated
with age, sex, P-wave duration, (mitral) valve disease, and the pres-
ence of AF. Moreover, patients with AF also had larger amounts of
amyloid in their appendages than patients in sinus rhythm. Regarding
the observation that patients undergoing mitral valve surgery had a
high prevalence of amyloid, Ro¨cken et al. speculated that high ANP
levels secondary to the valvular disease and atrial dilatation (stretch)
may have played a role.
Another study also investigated the presence of amyloid in atrial
appendages obtained from 72 patients during valve replacement sur-
gery.22 All patients had rheumatic valve disease and chronic AF, and
the findings in these patients were compared with patients with heart
failure and sinus rhythm. Amyloid was found in 46% of the valvular
patients compared with only 12% of the controls, and amyloid was
also related to the duration of AF. In addition, a study was performed
in heart specimens obtained from consecutive autopsied subjects,
mean age 75 years, 41 males.23 In 37 heart specimens either Grade 0
(no/trivial deposits) or Grade 3 (dense network/solid foci) was found.
Of these heart specimens, 27 had corresponding premortem ECGs,
with Grade 3 IAA being present in 14 cases and Grade 0 in 13 cases
(Figure 2). The ECG in as many as 10 of the 14 cases with Grade 3
IAA showed AF/atrial flutter (71%), whereas only 4 of the 13 cases
with Grade 0 IAA showed AF/atrial flutter (31%).
The mechanisms underlying AF in general are complex and involve
electrical, structural, and autonomic atrial remodelling processes.
Together, the processes affect the electrophysiological properties of
the atria, in particular conduction, thus setting the stage for AF. IAA is
likely operative in all these processes, but the most prominent aspect
is probably the effect on atrial conduction. Indeed, as demonstrated
by Ro¨cken et al.21 the deposition of amyloid fibrils impedes atrial con-
duction (prolonged P-waves). Conversely, they also provide data that
Figure 1 Representative electroanatomic bipolar voltage maps of
the left atrium of a patient with cardiac amyloidosis.White lines indi-
cate boundaries and analysed left atrial segments. The voltage scale
indicates all purple areas as normal voltage; all others are low volt-
age. Note the great extent of low-voltage area. AP, anteroposterior;
PA, posteroanterior. Reprinted with permission of Barbhaiya et al.17


































































































AF in turn may affect amyloid deposition, since AF was associated
with significantly higher amounts of amyloid compared with sinus
rhythm. Ro¨cken et al. thus speculate that AF is perhaps not an initi-
ator of amyloid deposition in IAA, but that it may promote further
deposition once the process has started.
Interrelations and potentially
vicious circles
The above data point to a scenario that two naturally occurring
peptides (TTR and ANP) with clear beneficial physiological func-
tions somehow begin to exert a detrimental effect on the heart
along with ageing, eventually leading to the clinical phenotypes of
HFpEF and AF. Moreover, although many of the above studies
show associations rather than causation and the data are not final,
there appear to be intricate interrelations between the compo-
nents of the processes involved, potentially leading to detrimental
vicious circles.
In brief, ageing is a risk factor for amyloidosis (senile amyloidosis),
leading to ATTRwt and/or IAA, depending on the protein involved
(TTR or ANP, respectively). In turn, ATTRwt may cause or promote
HFpEF, and vice versa, while IAA may cause AF, and vice versa.
Moreover, HFpEF and AF facilitate each other and senile amyloidosis
may thus also provide another piece of the puzzle explaining the
interaction between these two diseases (vicious twins). Finally, an
interesting intermediary role might be played by ANP, potentially
linking both HFpEF and AF with IAA. However, there are several
remaining issues to resolve. First, it is not fully understood how TTR
and ANP become amyloidogenic. Second, the same holds true for
how HFpEF facilitates ATTRwt and AF facilitates IAA. In addition,
ATTRwt and IAA are not mutually exclusive. More specifically, it is
conceivable that ATTRwt is not confined to the ventricles but also
directly affects the atria. Indeed, in the study by Ro¨cken et al., the
amyloid atrial deposits were immunoreactive for ANP in all 40 cases,
but four of these cases also showed additional TTR-positive amyloid
deposits. In addition, in a Cardiac Magnetic Resonance (CMR) study,
late gadolinium enhancement consistent with atrial amyloidosis was
observed in the atrial wall in as many as 17 (78%) of 22 patients with
cardiac amyloidosis, including eight patients with ATTRwt.24 If any-
thing is to be deduced from these data, it seems rather likely that the
two forms of senile amyloidosis will act in concert, once more setting
the stage for AF. Finally, although the concept is appealing, there is lit-
tle clinical evidence for the existence of a vicious circle between AF,
ANP and IAA. More work is needed to elucidate these issues, but it is
already clear that, besides the ventricles, the atria are an important
but underestimated site of action in senile cardiac amyloidosis
(ATTRwt, IAA) and its sequelae.
Of note, this review focusses on HFpEF but some patients with
ATTR with cardiac involvement ‘progress’ to heart failure with
reduced ejection fraction (HFrEF) and the interaction with AF then
probably changes, resembling more the interaction between HFrEF
and AF in general and AF playing a less prominent role, but this
remains to be investigated.
Diagnostic considerations
The clinical diagnosis of ATTRwt with cardiac involvement can be
challenging. Patients may present with a variety of symptoms and not
all patients are elderly men. Moreover, the typical cardiac findings
of low voltage ECG and concentric left ventricular hypertrophy
on the echocardiogram may not be present.7,25 Brain natriuretic
peptide levels are usually significantly elevated and more so than in
non-amyloidotic cardiomyopathy, while troponin levels are often
also raised. However, these biomarkers only provide circumstantial
evidence at best in terms of establishing the diagnosis.14,26. CMR
imaging with late gadolinium enhancement and T1 mapping may
be helpful but is not able to reliably differentiate between cardiac
amyloidosis due to ATTR or other types of amyloidosis.27 Instead, a
simple ‘bone-scintigram’ has emerged as a reliable, non-invasive
tool to diagnose cardiac amyloidosis due to ATTR (either ATTRm
or ATTRwt).28–30 (Figure 3). Importantly, this readily available,
non-invasive technique avoids the need for taking a myocardial
biopsy. Pros and cons of the above tests are summarized in
Supplementary material (Table S1) online.
Figure 2 Sirius red staining of left atrial tissue showing high grade
isolated atrial amyloidosis (x4) (upper panel). Immunostaining of left
atrial tissue in a patient with isolated atrial amyloidosis demonstrat-
ing the presence of atrial natriuretic peptide (x4) (lower panel).
Reprinted with permission of Ariyarajah et al.23

























Diagnosing IAA in the clinical setting is even more challenging.
Electrocardiographic features may raise suspicion, in particular a
prolonged and low voltage P-wave, AV-block, and paroxysmal AF,
but this is non-specific and clearly not sufficient to establish a def-
inite diagnosis. The role of CMR imaging has not yet been fully
defined, but detection of atrial amyloid in patients with cardiac
amyloidosis is feasible (Figure 3).24,31,32 However, these data
pertain to patients with ATTR and AL amyloidosis, but to our
knowledge no CMR imaging studies have been performed in IAA.
It is thus not yet possible to ascertain the presence of IAA in the
clinical setting.
Pharmacological considerations
Therapeutic management of HFpEF and AF (and the combination
thereof) is beyond the scope of this review and for this the reader is
referred to the guidelines.33,34 Of note, although these guidelines
Figure 3 Representative echocardiographic (A), cardiac magnetic resonance (B), cardiac magnetic resonance with late gadolinium enhancement
(C), and 99mTc-HDP scintigraphy (D) images of a patient with HFpEF due to ATTRwt. Note the hypertrophy, the late gadolinium enhancement (white
areas) both in left ventricle and the atria, as well as the pronounced uptake of tracer in the heart on the scintigram.


































































































generally also apply in the setting of concomitant amyloidosis, one
issue should be mentioned here and that is that use of digoxin and
calcium-antagonists for rate control for AF is not recommended
given the risk of toxicity due to possible binding of these agents to
amyloid fibrils. The focus here is on the pharmacological treat-
ment of amyloidosis. In general, treatment of ATTR can be divided
into three approaches: (i) stabilization of the TTR tetramers,
(ii) suppression of the production of TTR by the liver, and (iii) re-
moval of TTR amyloid deposits from tissues. An example of the
first approach is the use of Diflunisal. This compound prevents
dissociation of TTR into its monomers and has been shown to re-
tard progression of polyneuropathy caused by ATTRm although
no effect on cardiac involvement has been demonstrated as yet.
The other available TTR tetramer stabilizer is Tafamidis and this
agent does not have the NSAID side-effects of Diflunisal. It has al-
ready proved to be efficacious for neurological manifestations but
very recently, in the ATTR-ACT study, Tafamidis was also shown
to reduce all-cause mortality and cardiovascular-related hospital-
izations in patients with cardiac involvement.35 Of note, although
these are very promising results it is as yet uncertain whether
Tafamidis would also be beneficial in patients with concomitant
AF. The second approach entails gene-silencing, aimed at sup-
pressing the production of TTR by the liver by harnessing
small interfering ribonucleic acids (siRNA) or antisense oligonu-
cleotides (ASO). Two such suppressors are now available:
Patisiran (siRNA) and Inotersen (ASO).36,37 Both agents appear
to have favourable effects on polyneuropathy, while Patisiran pos-
sibly also stops further worsening of the cardiomyopathy, but
since this was only a secondary endpoint, it needs to be proven
in a new study. Finally, treatment with anti-serum amyloid P (SAP)
antibodies (Dezamizumab) after pre-treatment with CPHPC
(Miridesap) to remove circulating SAP is a promising third ap-
proach, aimed at removing amyloid fibrils from the tissues. Initial
results with these removers in patients with systemic amyloidosis
with liver, spleen and kidney involvement are promising.38,39 Of
note, although there is currently no treatment for IAA,
theoretically treatment with anti-SAP antibodies might work in
this setting, but this obviously needs to be proven.
Conclusions
Heart failure with preserved ejection fraction and AF are very com-
mon diseases that also often occur in combination, further aggravat-
ing each other. Senile amyloidosis, either due to TTR (ATTRwt) or
ANP (IAA) appears to play an important role in both diseases and in
their interaction. In terms of diagnostics, bone scintigraphy has be-
come available and affords an easy and reliable way to establish the
presence of cardiac ATTRwt. Moreover, pharmacological options
are now available or under development to treat ATTRwt and pos-
sibly also IAA, thereby potentially stopping, or even reversing, the
downhill course of some patients with HFpEF and AF.
Supplementary material
Supplementary material is available at European Heart Journal online.
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